Allergic rhinitis and sinusitis are chronic conditions of the airway and cause significant morbidity. Both can require pharmacotherapy with nonprescription products to relieve symptoms or with prescription products to treat the underlying pathophysiology. Because these diseases are prevalent conditions, the pharmacist is in the unique position of being the first health professional contact for many patients. The pharmacist can assist the patient in selection of nonprescription antihistamines, decongestants, and nasal saline sprays as well as provide instruction on the use of steam therapy, aromatic vapors, and warm compresses for the relief of symptoms. Equally important, the pharmacist can encourage patients to seek care from a physician when treatment with intranasal corticosteroids, antibiotics, and nonsedating antihistamines are needed.
Collins JG. Prevalence of selected chronic conditions: United States, 1990-1992. National Center for Health Statistics. Vital Health Stat. 1997; 10.
2.
Evans RI. Epidemiology and natural history of asthma, allergic rhinitis, and atopic dermatitis. In: Middleton E, Jr., Reed CE, Ellis EF, Adkinson NF, Jr., Yunginger JW, Busse WW, editors. Allergy Principles and Practice. St. Louis: Mosby-Year Book, Inc., 1993: 1109-1136.
3.
Schoenwetter WF. Allergic rhinitis: epidemiology and natural history. Allergy Asthma Proc. 2000; 21:1-6.
4.
Strachan D, Sibbald B, Weiland S, et al. Worldwide variations in prevalence of symptoms of allergic rhinoconjunctivitis in children: the International Study of Asthma and Allergies in Childhood (ISAAC). Pediatr Allergy Immunol. 1997; 8:161-176.
5.
Malone DC, Lawson KA, Smith DH, et al. A cost of illness study of allergic rhinitis in the United States. J Allergy Clin Immunol. 1997; 99:22-27.
6.
Storms W, Meltzer EO, Nathan RA, et al. The economic impact of allergic rhinitis. J Allergy Clin Immunol. 1997; 99:s820-s824.
7.
Ross RN. The costs of allergic rhinitis. Am J Manag Care. 1996; 2:285-290.
8.
Kozma CM, Sadik MK, Watrous ML. Economic outcomes for the treatment of allergic rhinitis. Pharmacoeconomics. 1996; 10:4-13.
9.
McMenamin P.Costs of hay fever in the United States in 1990. Ann Allergy. 1994; 73:35-39.
10.
Ray NF, Baraniuk JN, Thamer M, et al. Direct expenditures for the treatment of allergic rhinoconjunctivitis in 1996, including the contributions of related airway illnesses. J Allergy Clin Immunol. 1999; 103:401-407.
11.
Santos R, Cifaldi M, Gregory C, et al. Economic outcomes of a targeted intervention program: the costs of treating allergic rhinitis patients. Am J Manag Care. 1999; 5:S225-S234.
12.
White M.Mediators of inflammation and the inflammatory process. J Allergy Clin Immunol. 1999; 103:S378-S381.
Wang D, Smitz J, Waterschoot S, et al. An approach to the understanding of the nasal early-phase reaction induced by nasal allergen challenge. Allergy. 1997; 52:162-167.
15.
Howarth PH. Leukotrienes in rhinitis. Am J Respir Crit Care Med. 2000; 161:S133-S136.
16.
Kalinar M, Lemanske R.Rhinitis and Asthma. JAMA. 1992; 268:2807-2829.
17.
Brain DJ. Anatomy, physiology and ultrastructure of the nose. In: Mackay ID, editor. Rhinitis: mechanisms and management. New York: Royal Society of Medicine Services Limited, 1989: 11-31.
18.
Johnson DA, Hricik JG. The pharmacology of α-adrenergic decongestants. Pharmacotherapy. 1993; 13:110S-115S.
19.
Hogan MB, Grammer LC, Patterson R.Rhinitis. Ann Allergy. 1994; 72:293-302.
20.
Naclerio RM. Inhibition of mediator release during the early reaction to antigen. J Allergy Clin Immunol. 1992; 90:715-719.
21.
Naclerio RM. Allergic rhinitis. N Engl J Med. 1991; 325:860-869.
22.
Costa JJ, Weller PF, Galli SJ. The cells of the allergic response: mast cells, basophils, and eosinophils. JAMA. 1997; 278:1815-1822.
23.
Weiler JM, Bloomfield JR, Woodworth GG, et al. Effects of fexofenadine, diphenhydramine, and alcohol on driving performance. A randomized, placebo-controlled trial in the Iowa driving simulator [see comments]. Ann Intern Med. 2000; 132:354-363.
24.
Kay GG. The effects of antihistamines on cognition and performance. J Allergy Clin Immunol. 2000; 105:S622-S627.
25.
Meltzer EO. Comparative safety of H1 antihistamines. Ann Allergy. 1991; 67:625-633.
26.
Gilmore TM, Alexander BH, Mueller BA, et al. Occupational injuries and medication use. Am J Ind Med. 1996; 30:234-239.
27.
Katz RM. Treating the student with allergic rhinitis. Pediatric Asthma, Allergy & Immunology. 1996; 10:93-100.
28.
Kemp JP. Special considerations in the treatment of seasonal allergic rhinitis in adolescents: the role of antihistamine therapy. Clin Pediatr. (Phila). 1996; 35:383-389.
29.
Kay GG, Plotkin KE, Quig MB, et al. Sedating effects of AM/PM antihistamine dosing with evening chlorpheniramine and morning terfenadine. Am J Manag Care. 1997; 3:1843-1848.
30.
Dykewicz MS, Fineman S, editors. Diagnosis and management of rhinitis: Parameter documents of the joint task force on practice parameters in allergy, asthma, and immunology. Ann Allergy Asthma Immunol. 1998.
Simons FE, Watson WT, Chen XY, et al. The pharmacokinetics and pharmacodynamics of hydroxyzine in patients with primary biliary cirrhosis. J Clin Pharmacol. 1989; 29:809-815.
Ratner PH, Lim JC, Georges GC. Comparison of once-daily ebastine 20 mg, ebastine 10 mg, loratadine 10 mg, and placebo in the treatment of seasonal allergic rhinitis. The Ebastine Study Group. J Allergy Clin Immunol. 2000; 105:1101-1107.
35.
Kernan WN, Viscoli CM, Brass LM, et al. Phenylpropanolamine and the risk of hemorrhagic stroke. N Engl J Med. 2000; 343:1826-1832.
36.
Lau SK, Wei WI, Van Hasselt CA, et al. A clinical comparison of budesonide nasal aerosol, terfenadine and a combined therapy of budesonide and oxymetazoline in adult patients with perennial rhinitis. Asian Pac J Allergy Immunol. 1990; 8:109-115.
37.
van Cauwenberge P, Bachert C, Passalacqua G, et al. Consensus statement on the treatment of allergic rhinitis. European Academy of Allergology and Clinical Immunology. Allergy. 2000; 55:116-134.
38.
Weiner JM, Abramson MJ, Puy RM. Intranasal corticosteroids versus oral H1 receptor antagonists in allergic rhinitis: systematic review of randomised controlled trials. BMJ. 1998; 317:1624-1629.
39.
Lumry WR. A review of the preclinical and clinical data of newer intranasal steroids used in the treatment of allergic rhinitis. J Allergy Clin Immunol. 1999; 104:S150-S158.
40.
LaForce C.Use of nasal steroids in managing allergic rhinitis. J Allergy Clin Immunol. 1999; 103:S388-S394.
41.
Welsh PW, Stricker WE, Chu-Pin C. Efficacy of beclomethasone nasal solution, flunisolide, and cromolyn in relieving symptoms of ragweed allergy. Mayo Clin Proc. 1987; 62:125-134.
42.
Ratner PH, Paull BR, Findlay SR, et al. Fluticasone propionate given once daily is as effective for seasonal allergic rhinitis as beclomethasone dipropionate given twice daily. J Allergy Clin Immunol. 1992; 90:285-291.
43.
Drouin M, Yang WH, Bertrand B, et al. Once daily mometasone furoate aqueous nasal spray is as effective as twice daily beclomethasone dipropionate for treating perennial allergic rhinitis patients. Ann Allergy Asthma Immunol. 1996; 77:153-160.
44.
Juniper EF, Guyatt GH, Archer B, et al. Aqueous beclomethasone dipropionate in the treatment of ragweed pollen-induced rhinitis: further exploration of “as needed” use. J Allergy Clin Immunol. 1993; 92:66-72.
45.
Jen A, Baroody F, de Tineo M, et al. As-needed use of fluticasone propionate nasal spray reduces symptoms of seasonal allergic rhinitis. J Allergy Clin Immunol. 2000; 105:732-738.
46.
Small P, Houle PA, Day JH, et al. A comparison of triamcinolone acetonide nasal aerosol spray and fluticasone propionate aqueous solution spray in the treatment of spring allergic rhinitis. J Allergy Clin Immunol. 1997; 100:592-595.
47.
Pipkorn U, Pukander J, Suonpaa J, et al. Long-term safety of budesonide nasal aerosol: a 5.5-year follow-up study. Clin Allergy. 1988; 18:253-259.
48.
Davies RJ, Nelson HS. Once-daily mometasone furoate nasal spray: efficacy and safety of a new intranasal glucocorticoid for allergic rhinitis. Clin Ther. 1997; 19:27-38.
Schoelzel EP, Menzel ML. Nasal sprays and perforation of the nasal septum. JAMA. 1985; 253:2046.
51.
Bernstein IL. Is the use of benzalkonium chloride as a preservative for nasal formulations a safety concern? A cautionary note based on compromised mucociliary transport. J Allergy Clin Immunol. 2000; 105:39-44.
52.
Graf P.Adverse effects of benzalkonium chloride on the nasal mucosa: allergic rhinitis and rhinitis medicamentosa. Clin Ther. 1999; 21:1749-1755.
Wilson AM, McFarlane LC, Lipworth BJ. Effects of repeated once daily dosing of three intranasal corticosteroids on basal and dynamic measures of hypothalamic-pituitary-adrenal-axis activity. J Allergy Clin Immunol. 1998; 101:470-474.
55.
Wiseman LR, Benfield P.Intranasal fluticasone propionate. A reappraisal of its pharmacology and clinical efficacy in the treatment of rhinitis. Drugs. 1997; 53:885-907.
56.
Allen DB. Systemic effects of intranasal steroids: an endocrinologist’s perspective. J Allergy Clin Immunol. 2000; 106:S179-S190.
57.
Skoner DP, Rachelefsky GS, Meltzer EO, et al. Detection of growth suppression in children during treatment with intranasal beclomethasone dipropionate. Pediatrics. 2000; 105:E23.
58.
Lipworth BJ, Seckl JR. Measures for detecting systemic bioactivity with inhaled and intranasal corticosteroids. Thorax. 1997; 52:476-482.
59.
Schenkel EJ, Skoner DP, Bronsky EA, et al. Absence of growth retardation in children with perennial allergic rhinitis after one year of treatment with mometasone furoate aqueous nasal spray. Pediatrics. 2000; 105:E22.
60.
Agertoft L, Pedersen S.Effect of long-term treatment with inhaled budesonide on adult height in children with asthma. N Engl J Med. 2000; 343:1064-1069.
61.
Derby L, Maier WC. Risk of cataract among users of intranasal corticosteroids. J Allergy Clin Immunol. 2000; 105:912-916.
62.
White MV, Kaliner MA. Mediators of allergic rhinitis. J Allergy Clin Immunol. 1992; 90:699-704.
63.
Avunduk AM, Avunduk MC, Kapicioglu Z, et al. Mechanisms and comparison of anti-allergic efficacy of topical lodoxamide and cromolyn sodium treatment in vernal keratoconjunctivitis. Ophthalmology. 2000; 107:1333-1337.
64.
Juniper EF, Kline PA, Hargreave FE, et al. Comparison of beclomethasone dipropionate aqueous nasal spray, astemizole, and the combination in the prophylactic treatment of ragweed pollen-induced rhinoconjunctivitis. J Allergy Clin Immunol. 1989; 83:627-633.
65.
Ziment I.Recent advances in alternative therapies. Curr Opin Pulm Med. 2000; 6:71-78.
66.
Bielory L, Lupoli K.Herbal interventions in asthma and allergy. J Asthma. 1999; 36:1-65.
67.
Hochwald L.Natural allergy remedies. New Age. 2001; March/April, 36-40.
68.
Casale TB, Bernstein IL, Busse WW, et al. Use of an anti-IgE humanized monoclonal antibody in ragweed-induced allergic rhinitis. J Allergy Clin Immunol. 1997; 100:110-121.
69.
Racine-Poon A, Botta L, Chang TW, et al. Efficacy, pharmacodynamics, and pharmacokinetics of CGP 51901, an anti-immunoglobulin E chimeric monoclonal antibody, in patients with seasonal allergic rhinitis. Clin Pharmacol Ther. 1997; 62:675-690.
70.
Donnelly AL, Glass M, Minkwitz MC, et al. The leukotriene D4-receptor antagonist, ICI 204,219, relieves symptoms of acute seasonal allergic rhinitis. Am J Respir Crit Care Med. 1995; 151:1734-1739.
71.
Knapp HR. Reduced allergen-induced nasal congestion and leukotriene synthesis with an orally active 5-lipoxygenase inhibitor. N Engl J Med. 1990; 323:1745-1748.
72.
Meltzer EO, Malmstrom K, Lu S, et al. Concomitant montelukast and loratadine as treatment for seasonal allergic rhinitis: a randomized, placebo-controlled clinical trial. J Allergy Clin Immunol. 2000; 105:917-922.
73.
Wilson AM, Orr LC, Sims EJ, et al. Effects of monotherapy with intranasal corticosteroid or combined oral histamine and leukotriene receptor antagonists in seasonal allergic rhinitis. Clin Exp Allergy. 2001; 31:61-68.
74.
Task Force on Allergic Disorders: Promoting Best Practice. Raising the Standard of Care for Patients with Allergic Disorders. Executive Summary Report. American Academy of Allergy, Asthma & Immunology. 1998.
75.
The use of newer asthma and allergy medications during pregnancy. The American College of Obstetricians and Gynecologists (ACOG) and The American College of Allergy, Asthma and Immunology (ACAAI). Ann Allergy Asthma Immunol. 2000; 84:475-480.
76.
Matzke GR, Halstenson CE, Opsahl JA, et al. Pharmacokinetics of loratadine in patients with renal insufficiency. J Clin Pharmacol. 1990; 30:364-371.
77.
Juniper EF, Thompson AK, Ferrie PJ, et al. Validation of the standardized version of the Rhinoconjunctivitis Quality of Life Questionnaire. J Allergy Clin Immunol. 1999; 104:364-369.
78.
Juniper EF, Thompson AK, Ferrie PJ, et al. Development and validation of the mini Rhinoconjunctivitis Quality of Life Questionnaire. Clin Exp Allergy. 2000; 30:132-140.
79.
Diagnosis and Treatment of Acute Bacterial Rhinosinusitis Summary, Evidence Report/Technology Assessment: Number 9, March 1999. Agency for Health Care Policy and Research, Rockville, MD.
80.
Benson V, Marano MA. Current estimates from the National Health Interview Survey, 1995. Vital Health Stat. 101998; 1-428.
81.
Ray NF, Baraniuk JN, Thamer M, et al. Healthcare expenditures for sinusitis in 1996: contributions of asthma, rhinitis, and other airway disorders. J Allergy Clin Immunol. 1999; 103:408-414.
82.
Berrettini S, Carabelli A, Sellari-Franceschini S, et al. Perennial allergic rhinitis and chronic sinusitis: correlation with rhinologic risk factors. Allergy. 1999; 54:242-248.
Gliklich RE, Metson R.The health impact of chronic sinusitis in patients seeking otolaryngologic care. Otolaryngol Head Neck Surg. 1995; 113:104-109.
85.
Brooks I, Gooch WM, III, Jenkins SG, et al. Medical management of acute bacterial sinusitis. Recommendations of a clinical advisory committee on pediatric and adult sinusitis. Ann Otol Rhinol Laryngol Suppl. 2000; 182:2-20.
86.
Spector SL, Bernstein IL, Li JT, et al. Parameters for the diagnosis and management of sinusitis. J Allergy Clin Immunol. 1998; 102:S107-S144.
87.
Zacharisen MC, Kelly KJ. Allergic and infectious pediatric sinusitis. Pediatr Ann. 1998; 27:759-766.
88.
Jones NS. Acute and chronic sinusitis in children. Curr Opin Pulm Med. 2000; 6:221-225.
89.
Ramadan HH, Fornelli R, Ortiz AO, Rodman S.Correlation of allergy and severity of sinus disease. Am J Rhinol. 1999; 13:345-347.
90.
Bachert C, Van Cauwenberge PB. Inflammatory mechanisms in chronic sinusitis. Acta Otorhinolaryngol Belg. 1997; 51:209-217.
91.
Kramer MF, Ostertag P, Pfrogner E, Rasp G.Nasal interleukin-5, immunoglobulin E, eosinophilic cationic protein, and soluble intercellular adhesion molecule-1 in chronic sinusitis, allergic rhinitis, and nasal polyposis. Laryngoscope. 2000; 110:1056-1062.
92.
Min YG, Lee KS. The role of cytokines in rhinosinusitis [In Process Citation]. J Korean Med Sci. 2000; 15:255-259.
93.
Rudack C, Stoll W, Bachert C.Cytokines in nasal polyposis, acute and chronic sinusitis. Am J Rhinol. 1998; 12:383-388.
94.
Shapiro GG, Virant FS, Furukawa CT, et al. Immunologic defects in patients with refractory sinusitis. Pediatrics. 1991; 87:311-316.
95.
Marney SR. Pathophysiology of reactive airway disease and sinusitis. Ann Otol Rhinol Laryngol. 1996; 105:98-100.
96.
Senior BA, Kennedy DW. Management of sinusitis in the asthmatic patient. Ann Allergy Asthma Immunol. 1996; 77:6-15.
97.
Oliveira CA, Sole D, Naspitz CK, et al. Improvement of bronchial hyperresponsiveness in asthmatic children treated for concomitant sinusitis. Ann Allergy Asthma Immunol. 1997; 79:70-74.
98.
Slavin RG. Complications of allergic rhinitis: implications for sinusitis and asthma. J Allergy Clin Immunol. 1998; 101:S357-S360.
99.
Ikeda K, Tanno N, Tamura G, et al. Endoscopic sinus surgery improves pulmonary function in patients with asthma associated with chronic sinusitis. Ann Otol Rhinol Laryngol. 1999; 108:355-359.
100.
Senior BA, Kennedy DW, Tanabodee J, et al. Long-term impact of functional endoscopic sinus surgery on asthma. Otolaryngol Head Neck Surg. 1999; 121:66-68.
101.
Rachelefsky GS, Katz RM, Siegel SC. Chronic sinus disease with associated reactive airway disease in children. Pediatrics. 1984; 73:526-529.
102.
Antimicrobial treatment guidelines for acute bacterial rhinosinusitis. Sinus and Allergy Health Partnership. Otolaryngol Head Neck Surg. 2000; 123:5-31.
103.
Doern GV, Brueggemann AB, Huynh H, et al. Antimicrobial resistance with Streptococcus pneumoniae in the United States, 1997-98. Emerg Infect Dis. 1999; 5:757-765.
104.
Williams JW, Simel DL, Roberts L, et al. Clinical evaluation for sinusitis. Making the diagnosis by history and physical examination. Ann Intern Med. 1992; 117:705-710.
105.
Stewart MG, Sicard MW, Piccirillo JF, et al. Severity staging in chronic sinusitis: are CT scan findings related to patient symptoms?Am J Rhinol. 1999; 13:161-167.
106.
Bhattacharyya T, Piccirillo J, Wippold FJ. Relationship between patient-based descriptions of sinusitis and paranasal sinus computed tomographic findings. Arch Otolaryngol Head Neck Surg. 1997;123:1189-1192.
107.
Mainous AG, Zoorob RJ, Oler MJ, et al. Patient knowledge of upper respiratory infections: implications for antibiotic expectations and unnecessary utilization. J Fam Pract. 1997; 45:75-83.
108.
Wang EE, Einarson TR, Kellner JD, et al. Antibiotic prescribing for Canadian preschool children: evidence of overprescribing for viral respiratory infections. Clin Infect Dis. 1999; 29:155-160.
109.
Temple ME, Nahata MC. Pharmacotherapy of acute sinusitis in children. Am J Health Syst Pharm. 2000; 57:663-668.
110.
Laurier C, Lachaine J, Ducharme M.Economic evaluation of antibacterials in the treatment of acute sinusitis. Pharmacoeconomics. 1999; 15:97-113.
111.
Pichichero ME. Short course antibiotic therapy for respiratory infections: a review of the evidence. Pediatr Infect Dis J. 2000; 19:929-937.
112.
Levine HL. Functional endoscopic sinus surgery: evaluation, surgery, and follow-up of 250 patients. Laryngoscope. 1990; 100:79-84.
113.
Kaliner MA, Osguthorpe JD, Fireman P, et al. Sinusitis: bench to bedside. Current findings, future directions. J Allergy Clin Immunol. 1997; 99:S829-S848.
114.
Nakamura H, Kawasaki M, Higuchi Y, et al. Effects of sinus surgery on asthma in aspirin triad patients. Acta Otolaryngol. 1999; 119:592-598.
115.
Porta M, Jick H, Habakangas JA. Follow-up study of pseudoephedrine users. Ann Allergy. 1986; 57:340-342.
Westerveld GJ, Voss HP, van der Hee RM, et al. Inhibition of nitric oxide synthase by nasal decongestants. Eur Respir J. 2000; 16:437-444.
118.
Wawrose SF, Tami TA, Amoils CP. The role of guaifenesin in the treatment of sinonasal disease in patients infected with the human immunodeficiency virus (HIV). Laryngoscope. 1992; 102:1225-1228.
119.
Braun JJ, Alabert JP, Michel FB, et al. Adjunct effect of loratadine in the treatment of acute sinusitis in patients with allergic rhinitis. Allergy. 1997; 52:650-655.
120.
Meltzer EO, Orgel HA, Backhaus JW, et al. Intranasal flunisolide spray as an adjunct to oral antibiotic therapy for sinusitis. J Allergy Clin Immunol. 1993; 92:812-823.
121.
Kondo H, Nachtigal D, Frenkiel S, et al. Effect of steroids on nasal inflammatory cells and cytokine profile. Laryngoscope. 1999; 109:91-97.
122.
Scadding GK. Other anti-inflammatory uses of intranasal corticosteroids in upper respiratory inflammatory diseases. Allergy. 2000; 55Suppl 62:19-23.
123.
Meltzer EO, Charous BL, Busse WW, et al. Added relief in the treatment of acute recurrent sinusitis with adjunctive mometasone furoate nasal spray. J Allergy Clin Immunol. 2000; 106:630-637.
124.
Barlan IB, Erkan E, Bakir M, et al. Intranasal budesonide spray as an adjunct to oral antibiotic therapy for acute sinusitis in children. Ann Allergy Asthma Immunol. 1997; 78:598-601.
